Thailand and the compulsory licensing of efavirenz

New England Journal of Medicine

Volumn 356, Issue 6, 2007, Pages 544-546

  Steinbrook, Robert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; EFAVIRENZ; EMTRICITABINE; NEVIRAPINE; TENOFOVIR;

BIRTH DEFECT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LICENSING; LIVER TOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLIC HEALTH; RASH; SHORT SURVEY; THAILAND;

EID: 33846872349     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp068297     Document Type: Article

References (5)

1. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection. 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-43.
2. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: towards universal access: recommendations for a public health approach. 2006 Revision. (Accessed January 23, 2007, at http://www.who.int/hiv/pub/guidelines/en/.)
3. Announcement of the Department of Disease Control, Ministry of Public Health, Thailand, on the public use of patents for pharmaceutical products. November 29, 2006. (Accessed January 23, 2007, at http://www.cptech.org/ip/ health/cl/recent-examples.html.)
4. Progress on global access to HIV antiretroviral therapy: a report on "3 by 5" and beyond. Geneva: World Health Organization, March 2006. (Accessed January 23, 2007, at http://www.who.int/hiv/fullreport_en_highres.pdf. )
5. Okie S. Fighting HIV - lessons from Brazil. N Engl J Med 2006;354:1977-81.